STOCKHOLM, May 13, 2024
/PRNewswire/ -- Today, an extraordinary general meeting has been
held in SciBase Holding AB (publ) ("SciBase" or the
"Company"). The general meeting resolved in accordance with the
proposals presented in the notice to attend the meeting (which is
available on the Company's website
(www.scibase.com)).
Amendment of the articles of association
The general meeting resolved, in accordance with the board of
directors' three proposals, to amend §§ 4-5 of the articles of
association, entailing:
- that the articles of association shall be amended so that the
share capital shall be not less than SEK
10,065,000 and not more than SEK
40,260,000 and that the number of shares shall be not less
than 201,300,000 and not more than 805,200,000,
- that the articles of association shall be amended so that the
share capital shall be not less than SEK
10,780,000 and not more than SEK
43,120,000 and that the number of shares shall be not less
than 215,600,000 and not more than 862,400,000, and
- that the articles of association shall be amended so that the
share capital shall be not less than SEK
11,500,000 and not more than SEK
46,000,000 and that the number of shares shall be not less
than 230,000,000 and not more than 920,000,000.
The general meeting further resolved, in a accordance with the
board of directors' proposal, to authorize the board of
directors to register with the Swedish Companies Registration
Office the above resolution to amend the Articles of Association,
the limits of which for the minimum and maximum number of shares in
the Company are consistent with the total number of shares in the
Company after the rights issue announced on 5 April 2024 and the directed issues of units
that the board of directors resolved upon on 5 April 2024 (that were conditional upon the
subsequent approval of the general meeting).
Directed issues
The general meeting resolved, in accordance with the board of
directors' proposal, to approve the resolution made by the board of
directors on 5 April 2024, on a new
issue of a maximum of 74,136,510 units to Ribbskottet AB, Per Olof
Ejendal AB, Kåre Gilstring, Robert
Molander, MLJK Konsult AB, Klintemar Konsult AB,
Jesper Hoiland, Fredrik Mattsson, Stefan
Hansson, Theodor Invest AB, Ulti AB, Van Herk Investments
B.V., Morningside Group AB, Viktor
Drvota and Eric Terhaerdt.
The subscription price for each unit is SEK
0.42, corresponding to a subscription price of SEK 0.42 per share. Warrants of series TO 2 are
issued free of charge. The issue results in an increase in the
number of shares in the Company of a maximum of 74,136,510 shares,
entailing a maximum increase of the share capital of SEK 3,706,825.50, and a new issue of a maximum of
370,682,550 warrants of series TO 2 entitling to subscription of
370,682,550 shares in the Company, whereby the share capital may
increase by an additional maximum of SEK
18,534,127.50 if all issued warrants of series TO 2 are
exercised. In total, the share capital may increase by a maximum of
SEK 22,240,953.00.
The general meeting further resolved in accordance with the
board of directors' proposal to approve the resolution made by the
board of directors on 5 April 2024,
on a new issue of a maximum of 3,755,259 units to Matt Leavitt. The subscription price for each
unit is SEK 0.42, corresponding to a
subscription price of SEK 0.42 per
share. Warrants of series TO 2 are issued free of charge. The issue
results in an increase in the number of shares in the Company of a
maximum of 3 755 259 shares, entailing a maximum increase of the
share capital of SEK 187,762.95, and
a new issue of a maximum of 18,776,295 warrants of series TO 2
entitling to subscription of 18,776,295 shares in the Company,
whereby the share capital may increase by an additional maximum of
SEK 938,814.75 if all issued warrants
of series TO 2 are exercised. In total, the share capital may
increase by a maximum of SEK
1,126,577.70.
For additional information, please contact:
Pia Renaudin, VD, tel. +46732069802,
e-mail: pia.renaudin@scibase.com
Certified Advisor (CA):
Vator Securities
Tel: +46 8 580 065 99
Email: ca@vatorsec.se
About SciBase:
SciBase is a global medical technology company, specializing in
early detection and prevention in dermatology. SciBase develops and
commercializes Nevisense, a unique point-of-care platform that
combines AI (artificial intelligence) and advanced EIS technology
to elevate diagnostic accuracy, ensuring proactive skin health
management.
Our commitment is to minimize patient suffering, allowing
clinicians to improve and save lives through timely detection and
intervention and reduce healthcare costs.
Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in
dermatological advancements.
The Company has been on the Nasdaq First North Growth Market
exchange since June 2, 2015. Learn
more at www.scibase.com. All press releases and financial reports
can be found here: http://investors.scibase.se/en/pressreleases
This information was brought to you by Cision
http://news.cision.com.
https://news.cision.com/scibase/r/bulletin-from-the-extraordinary-general-meeting-in-scibase-holding-ab--publ-,c3977529
The following files are available for download:
https://mb.cision.com/Main/12371/3977529/2790414.pdf
|
SciBase Bulletin
EGM
|
View original
content:https://www.prnewswire.co.uk/news-releases/bulletin-from-the-extraordinary-general-meeting-in-scibase-holding-ab-publ-302143337.html